Geron Stock Rallies More Than 60% in a Year: Here's Why

For Geron Corporation (GERN) , 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia in June.  Geron’s shares have risen 61.1% in the past year against a decrease of 15.6% for the industry. Here we discuss some reasons for the same. Image Source: Zacks Investment ResearchGERN’s Rytelo Enjoys Strong Demand TrendsThe approval of Rytelo gave Geron ...